Skip to Main Content
Table 1.

Cytotoxicity of EpCAM-targeted immunoliposomes (SIL-Dox), nontargeted liposomes (SL-Dox), and free doxorubicin against EpCAM-positive (MCF-7 and SW2) and EpCAM-negative (RL) tumor cells

Cell lineFormulationIC50 (μmol/L)*
2 h24 h
MCF-7 Free doxorubicin 0.6 ± 0.2 0.15 ± 0.1 
 SIL-Dox (anti-EpCAM) 15 ± 3 5 ± 1 
 SL-Dox (nontargeted) >175 55 ± 10 
SW2 Free doxorubicin 5 ± 2 1.5 ± 0.5 
 SIL-Dox (anti-EpCAM) 60 ± 10 25 ± 5 
 SL-Dox (nontargeted) >175 80 ± 10 
RL Free doxorubicin 9 ± 1 2 ± 1 
 SIL-Dox (anti-EpCAM) >175 100 ± 10 
 SL-Dox (nontargeted) >175 120 ± 10 
Cell lineFormulationIC50 (μmol/L)*
2 h24 h
MCF-7 Free doxorubicin 0.6 ± 0.2 0.15 ± 0.1 
 SIL-Dox (anti-EpCAM) 15 ± 3 5 ± 1 
 SL-Dox (nontargeted) >175 55 ± 10 
SW2 Free doxorubicin 5 ± 2 1.5 ± 0.5 
 SIL-Dox (anti-EpCAM) 60 ± 10 25 ± 5 
 SL-Dox (nontargeted) >175 80 ± 10 
RL Free doxorubicin 9 ± 1 2 ± 1 
 SIL-Dox (anti-EpCAM) >175 100 ± 10 
 SL-Dox (nontargeted) >175 120 ± 10 
*

Cells were plated in 96-well culture plates and incubated with free doxorubicin or doxorubicin encapsulated in liposomes as described in Materials and Methods. Data are presented as mean IC50 ± SD (n = 3).

P < 0.001, compared with nontargeted SL-Dox (one-way ANOVA, Tukey's post test).

Close Modal

or Create an Account

Close Modal
Close Modal